| scholarly article | Q13442814 |
| P356 | DOI | 10.1191/0961203304LU1067SR |
| P698 | PubMed publication ID | 15462490 |
| P50 | author | Cheuk Chun Szeto | Q37840506 |
| P2093 | author name string | C W K Lam | |
| E K Li | |||
| C-K Wong | |||
| L-S Tam | |||
| P2860 | cites work | Leflunomide: mode of action in the treatment of rheumatoid arthritis | Q24675005 |
| Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus | Q29614922 | ||
| Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study | Q43692733 | ||
| Leflunomide for the treatment of systemic lupus erythematosus: comment on the article by McMurray | Q43772372 | ||
| Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. | Q44441787 | ||
| Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. | Q52225534 | ||
| A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. | Q52863944 | ||
| P433 | issue | 8 | |
| P921 | main subject | systemic lupus erythematosus | Q1485 |
| placebo | Q269829 | ||
| P304 | page(s) | 601-604 | |
| P577 | publication date | 2004-01-01 | |
| P1433 | published in | Lupus | Q6704846 |
| P1476 | title | Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus | |
| P478 | volume | 13 |
| Q33882490 | 4SC-101, a novel small molecule dihydroorotate dehydrogenase inhibitor, suppresses systemic lupus erythematosus in MRL-(Fas)lpr mice |
| Q38891757 | Combination therapy of leflunomide and glucocorticoids for the maintenance of remission in patients with IgG4-related disease: a retrospective study and literature review. |
| Q36443689 | Contemporary treatment of systemic lupus erythematosus: an update for clinicians. |
| Q37954539 | Current state of evidence on 'off-label' therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland--a consensus report |
| Q91934535 | Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases |
| Q90084618 | Efficacy and safety of leflunomide in IgA nephropathy: a systematic review and meta-analysis |
| Q38101015 | Efficacy and safety of nonbiologic immunosuppressants in the treatment of nonrenal systemic lupus erythematosus: a systematic review |
| Q36634248 | Emerging drug therapies for systemic lupus erythematosus |
| Q46484874 | Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study |
| Q92874652 | Integrated, multicohort analysis reveals unified signature of systemic lupus erythematosus |
| Q43061691 | Leflunomide in the treatment of rheumatoid arthritis |
| Q50788916 | Leflunomide plus oral prednisone in treatment of idiopathic membranous nephropathy: a retrospective clinical study of efficacy and safety. |
| Q37908152 | Leflunomide: dermatologic perspective |
| Q28274721 | Leflunomide: friend or foe for systemic lupus erythematosus? |
| Q36150789 | Leflunomide: long-term clinical experience and new uses |
| Q37754815 | Management of systemic lupus erythematosus in Chinese patients |
| Q36724093 | Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines |
| Q37754557 | Novel approaches to therapy for systemic lupus erythematosus: update 2005. |
| Q92625516 | Novel paradigms in systemic lupus erythematosus |
| Q37358239 | Reappraisal of the clinical use of leflunomide in rheumatoid arthritis and psoriatic arthritis |
| Q39218839 | Research and therapeutics-traditional and emerging therapies in systemic lupus erythematosus |
| Q52836583 | S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). |
| Q35953478 | Safety and efficacy of leflunomide in primary Sjögren's syndrome: a phase II pilot study. |
| Q90260400 | Safety, Pharmacokinetics, and Pharmacogenetics of Single-Dose Teriflunomide Sodium and Leflunomide in Healthy Chinese Subjects |
| Q38191835 | Systemic lupus erythematosus: a therapeutic challenge for the XXI century |
| Q34498515 | Systemic lupus erythematosus: review of synthetic drugs |
| Q38920440 | T-cell-directed therapies in systemic lupus erythematosus |
| Q26775707 | The Efficacy and Safety of Leflunomide for the Treatment of Lupus Nephritis in Chinese Patients: Systematic Review and Meta-Analysis |
| Q46146983 | The efficacy and safety of leflunomide therapy in lupus nephritis by repeat kidney biopsy |
| Q36577380 | The management of pediatric systemic lupus erythematosus |
| Q82718457 | Therapeutic effect of leflunomide on the development of experimental lupus nephritis in mice |
| Q37778588 | Toxicity and Monitoring of Immunosuppressive Therapy Used in Systemic Autoimmune Diseases |
| Q42728756 | Treatment of lupus nephritis |
| Q38271125 | Treatment of severe lupus nephritis: the new horizon. |
| Q38973692 | Trigger factors of cutaneous lupus erythematosus: a review of current literature. |
| Q37690745 | Update on emerging drug therapies for systemic lupus erythematosus |
Search more.